Mymetics Corporation Stock Other OTC
Equities
MYMX
US62856A1025
Biotechnology & Medical Research
Sales 2021 | 430K 458K | Sales 2022 | 1.03M 1.1M | Capitalization | 8.51M 9.07M |
---|---|---|---|---|---|
Net income 2021 | -4M -4.26M | Net income 2022 | -4M -4.26M | EV / Sales 2021 | 177 x |
Net Debt 2021 | 67.1M 71.51M | Net Debt 2022 | 71.68M 76.4M | EV / Sales 2022 | 78 x |
P/E ratio 2021 |
-1.86
x | P/E ratio 2022 |
-1.77
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 48.72% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 09-06-30 | |
Mario Amacker
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Staehelin
BRD | Director/Board Member | 76 | 07-07-01 |
Ulrich Burkhard
BRD | Director/Board Member | 63 | 12-03-22 |
Marcel B. Rüegg
BRD | Director/Board Member | - | 23-01-15 |
1st Jan change | Capi. | |
---|---|---|
-3.39% | 102B | |
+2.61% | 96.84B | |
-1.02% | 21.48B | |
-18.14% | 20.82B | |
-7.42% | 18.6B | |
-40.70% | 16.81B | |
-26.89% | 13.78B | |
+1.12% | 13.4B | |
+22.25% | 11.06B |